.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
McKesson
Farmers Insurance
Chubb
Deloitte
Citi
AstraZeneca
Merck
Mallinckrodt
UBS

Generated: September 23, 2017

DrugPatentWatch Database Preview

LIORESAL Drug Profile

« Back to Dashboard

What is the patent landscape for Lioresal, and when can generic versions of Lioresal launch?

Lioresal is a drug marketed by Novartis and Saol Theraps Res Ltd and is included in two NDAs.

The generic ingredient in LIORESAL is baclofen. There are eighteen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the baclofen profile page.

Summary for Tradename: LIORESAL

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list76
Clinical Trials: see list2
Patent Applications: see list4,607
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LIORESAL at DailyMed

Pharmacology for Tradename: LIORESAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
LIORESAL
baclofen
TABLET;ORAL017851-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Saol Theraps Res Ltd
LIORESAL
baclofen
INJECTABLE;INTRATHECAL020075-001Jun 17, 1992APRXYesYes► Subscribe► Subscribe► Subscribe
Novartis
LIORESAL
baclofen
TABLET;ORAL017851-003Jan 20, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Saol Theraps Res Ltd
LIORESAL
baclofen
INJECTABLE;INTRATHECAL020075-003Nov 7, 1996APRXYesYes► Subscribe► Subscribe► Subscribe
Saol Theraps Res Ltd
LIORESAL
baclofen
INJECTABLE;INTRATHECAL020075-002Jun 17, 1992APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LIORESAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
LIORESAL
baclofen
TABLET;ORAL017851-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Novartis
LIORESAL
baclofen
TABLET;ORAL017851-003Jan 20, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Accenture
Queensland Health
Teva
Chinese Patent Office
Chubb
Harvard Business School
Cerilliant
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot